Ondansetrone Teva

Ondansetron, the active ingredient in Ondansetrone Teva, is a 5‑HT3 receptor antagonist presented as a tablet for oral use. It helps prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery.

GNH USA supplies Ondansetrone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of emesis in patients receiving cytotoxic drugs. Radiation‑induced nausea and vomiting: lessens acute nausea during cancer radiotherapy. Postoperative nausea and vomiting: prevents emesis after surgical procedures.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: mild cramping.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Serotonin syndrome: agitation, hyperthermia, neuromuscular abnormalities. - Cardiac arrhythmia: irregular heartbeat. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Ondansetrone Teva, consider the following safety points.

Assess cardiac history: monitor QT interval in patients with known heart disease. Review concomitant medications: avoid or adjust drugs that also prolong QT. Use with caution in hepatic impairment: dose may need adjustment. Use with caution in renal impairment: monitor renal function. Pregnancy and lactation: weigh potential benefits against risks; consult a specialist. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension. - Other QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmia. - Carbamazepine: induces metabolism, reducing ondansetron efficacy.

Moderate Interactions (Monitor Closely): - Aprepitant: may enhance antiemetic effect; monitor for additive QT prolongation. - Warfarin: possible alteration of anticoagulant effect; check INR. - Oral contraceptives: may reduce hormonal efficacy; advise alternative contraception if needed.